Allarity Therapeutics ends $6 million stock purchase deal with Tumim Stone Capital

Allarity Therapeutics disclosed in an 8-K filing that on October 28, 2026, it terminated the Common Stock Purchase Agreement dated January 28, 2026 with Tumim Stone Capital LLC, effective as of that date.¹

The agreement had given Allarity flexibility rather than an obligation to raise capital. It allowed the company to sell up to $6.0 million in newly issued common shares to Tumim at its own discretion, subject to the deal's terms and limits.¹ Pricing for any such sales was not fixed in advance. The purchase price for each sale was set by a formula tied to the stock's volume-weighted average price over the relevant pricing period.¹ The shares covered by the arrangement had been registered under Allarity's Form S-3 registration statement, file number 333-291906, through a prospectus supplement dated January 28, 2026.¹

Allarity said the termination was tied to a shift in its capital-raising approach. The company said it chose to end the agreement as it pursues other financing options.¹ The wind-down came without added cost. No early termination penalty applies under the agreement as a result of the termination.¹ Allarity will not sell any further shares to Tumim under the agreement going forward.¹ Some obligations will carry on regardless. Certain provisions designed to survive termination, such as indemnification duties and specified expense obligations, remain binding under their original terms.¹

The underlying purchase agreement had first been filed as an exhibit to Allarity's 8-K submitted to the SEC on January 29, 2026.¹ The termination filing was signed by CEO Thomas H. Jensen on October 30, 2026.